A Shift on “Pay for Delay” — Reopening Doors for Pharmaceutical Competition? — NEJM
A Shift on “Pay for Delay” — Reopening Doors for Pharmaceutical Competition? — NEJM:
'via Blog this'
posted by Unknown @ 9:53 AM
0 Comments
research law posts
I am a practicing attorney specializing in research-related legal issues, such as clinical research contracts, human subjects, research ethics and misconduct, and intellectual property originating from research activity. This blog is primarily to post links to cases, regulations, laws and policies, and other items that may be of interest to lawyers and research administrators in universities, hospitals, government research organizations, and commercial labs.
Saturday, November 3, 2012
Previous Posts
- The Exclusion IllusIon
- America's future : The Lancet
- How Much Would You Give to Save a Dying Bird? Pati...
- Comparing Local and Regional Variation in Health C...
- Growing Pains for the Medicare Hospice Benefit — NEJM
- Risk, Responsibility, and Generic Drugs — NEJM
- Medicare's Enduring Struggle to Define “Reasonable...
- Heavy prenatal alcohol linked to childhood brain d...
- The 1000 Genomes Project more than doubles catalog...
- USDOJ: US Attorney's Office - Western District of ...
Subscribe to
Posts [Atom]
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home